Compared with patients with SETD2 nonmutant cancer, patients with SETD2 mutant cancer harbored more MMR mutant genes (MSH6, 1.24% vs.14.38%; MSH2, 0.98% vs.11.73%; MLH1, 1.06% vs.8.41%; PMS2, 0.98% vs.9.73%; P < 0.0001 for all four genes). This evidence concerns the gene MRC1 and cancer.